Ready pack® system

NovaPure® components have quality built in from the start. West has developed a comprehensive quality target product profile (QTPP) based on the needs of our customers and end users.

With glass-like transparency, but superior break resistance and low risk of chemical interactions, Daikyo Crystal Zenith® vials can help avoid issues including delamination, and particulates.

The Daikyo Crystal Zenith® Insert Needle and Luer Lock Syringe systems were designed to maintain purity, integrity and efficacy of premium biopharmaceutical therapies.

An ideal choice for single- and multi-dose drugs, West components for prefillable systems help to ensure a more consistent injection rate to help patients receive accurate dosing with their treatment regimen.

The West Contract Manufacturing team is focused on serving the needs of healthcare companies by providing a single-source solution from product conceptualization through manufacturing and final packaging.  

Reconstitution devices enhance drug reconstitution, mixing and transfer through advanced technologies.

The SelfDose patient-controlled injector is an off-the-shelf delivery system that is ergonomically designed for optimal patient administration.

West offers analytical services for specialized testing and analysis to evaluate the compatibility of drug products with their packaging or administration system for pharmaceutical and biopharma customers.

Delivery devices such as multi-use pens or pen injectors demand cartridge technology that’s predictable and safe, with tight dimensional tolerances, and that may be suitable for high-viscosity drugs and various storage  conditions. See what West offers to help customers  address these challenges.

Seals are a crucial part of a vial system. The selection of an appropriate seal is critical to ensuring container closure integrity, drug protection, user convenience and safety.

West stoppers protect drugs from environmental impact and help maintain quality and safety. 

The Daikyo® Crystal Zenith® (CZ) 2.25mL insert needle is a break-resistant, polymer syringe of choice to protect larger volume sensitive molecules during self-administration. For drug developers wishing to avoid glass, this syringe system protects delicate molecules as there is no silicone oil added for fu...

West and Corning Launch Viridian™ Vials that provide both performance and sustainability to the healthcare industry

There are two major themes that involve primary packaging components in the revised EU GMP Annex 1 issued in August 2023. This recent revision includes: Implementing a holistic Contamination Control Strategy (CCS) Container Closure Integrity (CCI) because a properly seated stopper represents an adequate microbiological barrier. Pharmaceutical manufacturers must develop a CCS detailing the risks and mitigations within their operations, associated with contamination event opportunities with the emphasis being on personnel awareness, quality culture and controls, with focus on the principles involved in the protection of sterile product during the manufacturing, packaging and distribution processes.
This is why it is important to consider packaging decisions early in the development process. We will examine how primary packaging materials can impact your CCS and showcase West’s approach to mitigating risk on behalf of drug developers.

4040/40 elastomer formulation was designed with ‘future in mind’ to meet the ever-increasing performance & quality standards expected of primary drug packaging. The presentation will summarize the extensive Quality by Design (QbD) process that was undertaken to develop this new formulation as well as considerations taken for closure design dedicated for Lyophilization applications. Details of the extensive characterization that was performed as part of product development as well as data to demonstrates the overall performance of the new rubber formulation for lyophilization stoppers with respect to Extractables/Leachables, Particulates, Moisture, Container Closure Integrity (CCI), Particles and Manufacturability will be presented.

Our healthcare industry is evolving. The move from IV to SC injection is being driven by lifecycle management, biosimilar adoption, and the hospital to home trend. Molecules are getting more complex, and patients drive the preference for self-administration resulting in the need for more complex combination product development and quick scale up. We will present innovative solutions to these challenges to help speed up drug development and enable patient choice with: A 2.25mL polymer container system for auto-injectors which protects sensitive molecules A large volume cartridge plunger to enable primary containment within an on-body delivery system A small pack, high quality glass containment system to enable quick delivery in early-stage development